Changzhou No.2 People's Hospital is the lead sponsor of 7 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Pirtobrutinib, Pola-R-Chp and R-Chop. The most-studied condition is DLBCL - Diffuse Large B Cell Lymphoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
NCT06405113 · ClinicalTrials.gov ↗ · Gastric Cancer
|
Phase 2 | Recruiting | 2024-06 | China |
|
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
NCT06337474 · ClinicalTrials.gov ↗ · Thrombocytopenia Alloimmune
|
Phase EARLY_PHASE1 | Recruiting | 2024-08 | China |
|
Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters
NCT06964867 · ClinicalTrials.gov ↗ · Vitreous Floaters, Anxiety
|
Not applicable | Recruiting | 2023-12 | China |
|
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma
NCT07744750 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL
|
Phase 2 | Not yet open | 2026-08 | China |
|
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
NCT07744737 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
Drugs: Pirtobrutinib, R-Chop |
Phase 2 | Not yet open | 2026-07 | China |
|
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
NCT07744724 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Drugs: Pirtobrutinib, Pola-R-Chp |
Phase 2 | Not yet open | 2026-07 | China |
|
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis
|
Phase 1 | Not yet open | 2025-05 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 7 | 3 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| The First Affiliated Hospital of Xiamen University | 4 |
Sponsors with the most current trials registered for this condition.
Changzhou No.2 People's Hospital is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are Pirtobrutinib (2), Pola-R-Chp (1) and R-Chop (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.